Ratings MedPlus Health Services Limited

Equities

MEDPLUS

INE804L01022

Delayed NSE India S.E. Other stock markets 04:49:42 2024-05-22 EDT			5-day change	1st Jan Change
696.8 ^INR	-1.28%		-1.08%	-7.19%

05-05	Optival Health Solutions Private Limited Received Order for Temporarily Suspending the Operations of Store situated at Prakash Nagar Kurnool District Andra Pradesh, C.B Pura Road and MB Road Kolar, Karnataka for seven days each store	CI
03-25	Medplus Health Services Arm Gets Order for Temporary Suspension of Operations	MT

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's profit outlook over the next few years is a strong asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
With an expected P/E ratio at 162.1 and 74.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	ESG Refinitiv
MEDPLUS HEALTH SERVICES LIMITED	-7.19%	1.01B	-
WALGREENS BOOTS ALLIANCE, INC.	-36.12%	14.39B	B-
JD HEALTH INTERNATIONAL INC.	-27.49%	11.63B	B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-25.47%	6.41B	B
MATSUKIYOCOCOKARA & CO.	-7.51%	6.23B	C+
YIFENG PHARMACY CHAIN CO., LTD.	+15.31%	6.45B	C
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+74.92%	5.1B	C
NAHDI MEDICAL COMPANY	-2.77%	4.64B	D-
CLICKS GROUP LIMITED	-8.67%	3.92B	B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-10.64%	3.5B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes